Farxiga extended in the US for heart failure
9 May 2023 Farxiga extended in the US to reduce risk of cardiovascular death and hospitalisation for heart failure to a broader range of patients FDA approval means patients with heart failure can benefit from Farxigaregardless of left ventricular ejection fraction status AstraZeneca's Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death, hospitalisation for heart failure (hHF) and urgent heart failure (HF) visits in adults with HF. The approval by the Food and Drug Administration (FDA) was based on positive results from the DELIVER